Welcome to LookChem.com Sign In|Join Free

CAS

  • or

393509-23-4

Post Buying Request

393509-23-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

393509-23-4 Usage

General Description

2-(5-Bromo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is a chemical compound with a complex structure containing a cyclopenta[b]indol ring system substituted with bromine, fluorine, and acetic acid functional groups. 2-(5-BroMo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid may have potential pharmaceutical applications due to its unique structure, which could potentially interact with biological targets in the body. It may also have uses in organic synthesis and medicinal chemistry as a building block for creating new chemical entities with specific pharmacological properties. The compound's specific biological activity and potential medical uses would need to be further investigated through laboratory and clinical studies.

Check Digit Verification of cas no

The CAS Registry Mumber 393509-23-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,9,3,5,0 and 9 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 393509-23:
(8*3)+(7*9)+(6*3)+(5*5)+(4*0)+(3*9)+(2*2)+(1*3)=164
164 % 10 = 4
So 393509-23-4 is a valid CAS Registry Number.
InChI:InChI=1/C13H11BrFNO2/c14-10-5-7(15)4-9-8-2-1-6(3-11(17)18)12(8)16-13(9)10/h4-6,16H,1-3H2,(H,17,18)

393509-23-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(5-bromo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid

1.2 Other means of identification

Product number -
Other names Cyclopent[b]indole-3-acetic acid,5-bromo-7-fluoro-1,2,3,4-tetrahydro

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:393509-23-4 SDS

393509-23-4Relevant articles and documents

Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524)

Sturino, Claudio F.,O'Neill, Gary,Lachance, Nicolas,Boyd, Michael,Berthelette, Carl,Labelle, Marc,Li, Lianhai,Roy, Bruno,Scheigetz, John,Tsou, Nancy,Aubin, Yves,Bateman, Kevin P.,Chauret, Nathalie,Day, Stephen H.,Lévesque, Jean-Fran?ois,Seto, Carmai,Silva, Jose H.,Trimble, Laird A.,Carriere, Marie-Claude,Denis, Danielle,Greig, Gillian,Kargman, Stacia,Lamontagne, Sonia,Mathieu, Marie-Claude,Sawyer, Nicole,Slipetz, Deborah,Abraham, William M.,Jones, Tom,McAuliffe, Malia,Piechuta, Hana,Nicoll-Griffith, Deborah A.,Wang, Zhaoyin,Zamboni, Robert,Young, Robert N.,Metters, Kathleen M.

, p. 794 - 806 (2007/10/03)

The discovery of the potent and selective prostaglandin D2 (PGD2) receptor (DP) antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro-5- (methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (13) is presented. Initial lead antagonists 6 and 7 were found to be potent and selective DP antagonists (DP Ki = 2.0 nM for each); however, they both suffered from poor pharmacokinetic profiles, short half-lives and high clearance rates in rats. Rat bile duct cannulation studies revealed that high concentrations of parent drug were present in the biliary fluid (Cmax = 1100 μM for 6 and 3900 μM for 7). This pharmacokinetic liability was circumvented by replacing the 7-methylsulfone substituent present in 6 and 7 with a fluorine atom resulting in antagonists with diminished propensity for biliary excretion and with superior pharmacokinetic profiles. Further optimization led to the discovery of the potent and selective DP antagonist 13.

METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS

-

Page/Page column 43, (2008/06/13)

A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

-

Page/Page column 76, (2010/11/08)

The present invention encompasses compounds of Formula (I); as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 393509-23-4